Log In
Print
BCIQ
Print
Print this Print this
 

Nivestim, filgrastim

  Manage Alerts
Collapse Summary General Information
Company Hospira Inc.
DescriptionHuman granulocyte colony-stimulating factor (G-CSF) biosimilar version of Neupogen filgrastim from Amgen
Molecular Target Granulocyte colony-stimulating factor (G-CSF) receptor (CSF3R) (CD114)
Mechanism of ActionGranulocyte colony stimulating factor (G-CSF) receptor (CD114) agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationNeutropenia
Indication DetailsPrevent febrile neutropenia and to reduce the duration of chemotherapy-induced neutropenia; Treat neutropenia
Regulatory Designation

EU - Biosimilar (Prevent febrile neutropenia and to reduce the duration of chemotherapy-induced neutropenia);
EU - Biosimilar (Treat neutropenia)

Partner

Alvogen Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today